Compare MEC & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEC | BBOT |
|---|---|---|
| Founded | 1945 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.1M | 442.6M |
| IPO Year | 2019 | 2024 |
| Metric | MEC | BBOT |
|---|---|---|
| Price | $15.76 | $2.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $37.00 | $23.55 |
| AVG Volume (30 Days) | 406.4K | ★ 568.4K |
| Earning Date | 11-03-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $14.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.42 | $2.51 |
| 52 Week High | $38.76 | $14.87 |
| Indicator | MEC | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 20.50 |
| Support Level | $14.36 | N/A |
| Resistance Level | $18.84 | $9.36 |
| Average True Range (ATR) | 0.85 | 0.22 |
| MACD | 0.39 | 0.10 |
| Stochastic Oscillator | 86.12 | 4.96 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, powersports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly, and logistic services.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.